• Je něco špatně v tomto záznamu ?

Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review

L. Gorecki, E. Reznickova, V. Krystof, M. Rezacova, M. Ceckova, J. Korabecny

. 2025 ; 35 (2) : 137-164. [pub] 20250105

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010057

INTRODUCTION: Approximately one-third of all AML patients have a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene, which is associated with a poor prognosis in these individuals. The 2017 approval of midostaurin, the first FLT3 inhibitor, spurred extensive development of more potent and selective inhibitors with an improved safety profile. AREAS COVERED: This review analyzes patent inventions for the treatment of AML using FLT3 inhibitors, covering developments from the earliest to the most recent, disclosed in 2024. Our search using the global Espacenet database identified numerous compounds with low nanomolar inhibitory concentrations against FLT3-ITD and FLT3-TKD mutants. These compounds have shown promise in preclinical studies. Co-inhibition strategies and combinatorial therapies to overcome resistance and enhance anti-leukemic efficacy are also discussed. EXPERT OPINION: Recent patents highlight advances in the field of FLT3 inhibitors with a focus on overcoming resistance, improving selectivity and potency. Future strategies may include third-generation inhibitors such as type III allosteric inhibitors, irreversible inhibitors, or PROTACs. Personalized medicine approaches utilizing genetic profiling to tailor therapies are emphasized. Exploration of novel combination regimens with emerging therapies like CAR T-cell therapy, immune checkpoint inhibitors, and small molecules targeting critical AML pathways is ongoing to further enhance anti-leukemic efficacy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010057
003      
CZ-PrNML
005      
20250429135249.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/13543776.2024.2446224 $2 doi
035    __
$a (PubMed)39718422
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gorecki, Lukas $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czech Republic $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000247916556
245    10
$a Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review / $c L. Gorecki, E. Reznickova, V. Krystof, M. Rezacova, M. Ceckova, J. Korabecny
520    9_
$a INTRODUCTION: Approximately one-third of all AML patients have a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene, which is associated with a poor prognosis in these individuals. The 2017 approval of midostaurin, the first FLT3 inhibitor, spurred extensive development of more potent and selective inhibitors with an improved safety profile. AREAS COVERED: This review analyzes patent inventions for the treatment of AML using FLT3 inhibitors, covering developments from the earliest to the most recent, disclosed in 2024. Our search using the global Espacenet database identified numerous compounds with low nanomolar inhibitory concentrations against FLT3-ITD and FLT3-TKD mutants. These compounds have shown promise in preclinical studies. Co-inhibition strategies and combinatorial therapies to overcome resistance and enhance anti-leukemic efficacy are also discussed. EXPERT OPINION: Recent patents highlight advances in the field of FLT3 inhibitors with a focus on overcoming resistance, improving selectivity and potency. Future strategies may include third-generation inhibitors such as type III allosteric inhibitors, irreversible inhibitors, or PROTACs. Personalized medicine approaches utilizing genetic profiling to tailor therapies are emphasized. Exploration of novel combination regimens with emerging therapies like CAR T-cell therapy, immune checkpoint inhibitors, and small molecules targeting critical AML pathways is ongoing to further enhance anti-leukemic efficacy.
650    12
$a tyrosinkinasa 3 podobná fms $x antagonisté a inhibitory $x genetika $7 D051941
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x farmakoterapie $x genetika $7 D015470
650    12
$a patenty jako téma $7 D010330
650    12
$a mutace $7 D009154
650    12
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a zvířata $7 D000818
650    12
$a protinádorové látky $x farmakologie $7 D000970
650    12
$a chemorezistence $7 D019008
650    _2
$a vyvíjení léků $7 D000076722
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a staurosporin $x analogy a deriváty $x farmakologie $7 D019311
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Reznickova, Eva $u Department of Experimental Biology, Faculty of Science, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000347732850
700    1_
$a Krystof, Vladimir $u Department of Experimental Biology, Faculty of Science, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000158382118 $7 xx0097406
700    1_
$a Rezacova, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000153702290 $7 nlk20020124956
700    1_
$a Ceckova, Martina $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000329367212 $7 xx0049092
700    1_
$a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000169777596 $7 xx0119837
773    0_
$w MED00181402 $t Expert opinion on therapeutic patents $x 1744-7674 $g Roč. 35, č. 2 (2025), s. 137-164
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39718422 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135245 $b ABA008
999    __
$a ok $b bmc $g 2311430 $s 1247138
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 35 $c 2 $d 137-164 $e 20250105 $i 1744-7674 $m Expert opinion on therapeutic patents $n Expert Opin Ther Pat $x MED00181402
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace